



Correction to: Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab

Pratima Chowdary¹

Published online: 11 June 2018
© Springer International Publishing AG, part of Springer Nature 2018

Correction to: Drugs
<https://doi.org/10.1007/s40265-018-0922-6>

Figure 1

The legend, which reads

Mechanisms of action of monoclonal antibodies against tissue factor pathway inhibitor (TFPI)

Should read

TFPI mechanism of action and inhibition by anti-TFPI antibodies. **a** Tissue factor (TF) based initiation of coagulation and generation of FXa by the extrinsic tenase complex (FVIIa.TF.FX). **b** Inhibition of FXa and FVIIa by TFPI. **c** Binding of the different Kunitz (K) domains by the various anti-TFPI antibodies.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s40265-018-0922-6>.

✉ Pratima Chowdary
p.chowdary@ucl.ac.uk

¹ Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, Pond Street, London NW3 2 QG, UK